The goals for the Biomarker Validation Laboratory-called the UCLA Defined Tumor-Marker Core (D-TEC)-are to: 1. Optimally coordinate a consortium of currently operational laboratories for the direct purpose of evaluating and analyzing any and all identified markers of tumorigenesis. These laboratories include: Human Tissue Research Center (tissue procurement, sectioning, and histology), Tissue Analysis Laboratories (conventional immunohistochemistry, in situ hybridization, high throughput tissue microarray), Molecular Pathology Laboratories (gene expression, chromosomal abnormalities, polymorphism, high throughput array-based mutation analysis), Immunoassay Laboratory (ELISA, Western blot analysis), and Cellular Analysis Laboratories (flow cytometry, cytology, chromosomal analysis, cytogenetics) These laboratories are all in the UCLA School of Medicine (the Department of Pathology and Laboratory Medicine, the Department of Human Genetics, and the Jonsson Comprehensive Cancer Center) and therefore, have an established interaction and collaboration. 2. Coordinate the infrastructure for a thoughtful, yet rapid and flexible mechanism for study design, implementation, data collection, and information analysis. This infrastructure consists of distinguished faculty at UCLA which includes: the Core Laboratory Directors, an Internal Advisory Board committed to assisting in project design and strategic planning, and Bioinformatics core with combined expertise in biostatistics, bioinformatics, and data analysis and mining, and a Pathology Consultation Core for correlation of pathology diagnosis with a marker expression. 3. Establish a """"""""Development Study"""""""" which will specifically focus on the production of tumor- specific tissue arrays to be used as one of the high throughput techniques for tumor marker evaluation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA086366-02
Application #
6362766
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J2))
Project Start
2000-05-16
Project End
2005-02-28
Budget Start
2001-03-01
Budget End
2002-02-28
Support Year
2
Fiscal Year
2001
Total Cost
$676,070
Indirect Cost
Name
University of California Los Angeles
Department
Surgery
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hamilton, Nalo; Austin, David; Márquez-Garbán, Diana et al. (2017) Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci 18:
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Hong, Candice Sun; Graham, Nicholas A; Gu, Wen et al. (2016) MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep 14:1590-1601
Ho, Melissa E; Quek, Sue-Ing; True, Lawrence D et al. (2016) Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. Oncotarget 7:15747-56
Mah, Vei; Alavi, Mohammad; Márquez-Garbán, Diana C et al. (2015) Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. PLoS One 10:e0127600
Sun, Qiao-Yang; Ding, Ling-Wen; Xiao, Jin-Fen et al. (2015) SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway. J Pathol 235:559-70
Hamilton, Nalo; Márquez-Garbán, Diana; Mah, Vei et al. (2015) Biologic roles of estrogen receptor-? and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int 2015:925703
Alavi, Mohammed; Mah, Vei; Maresh, Erin L et al. (2015) High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer 15:655
Tian, Yuan; Choi, Caitlin H; Li, Qing Kay et al. (2015) Overexpression of periostin in stroma positively associated with aggressive prostate cancer. PLoS One 10:e0121502
Hamilton, Nalo; Marquez-Garban, Diana; Mah, Vei H et al. (2015) Estrogen Receptor-? and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog 20:373-90

Showing the most recent 10 out of 45 publications